Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00651859 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
NCT00651859 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 111 participants.
The verdict
NCT00651859, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
Study Summary
This study evaluates the safety and efficacy of once-daily bimatoprost 0.03% and 0.01% ophthalmic solutions compared with once-daily administered bimatoprost vehicle ophthalmic solution for 2 weeks in ethnically Japanese patients with open-angle glaucoma or ocular hypertension
Interventions
- DRUG Bimatoprost 0.01% Ophthalmic Solution
- DRUG Bimatoprost 0.03% Ophthalmic Solution
- DRUG Bimatoprost Vehicle Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2002-11 |
| Est. Completion | 2004-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00651859
The ClinicalTrials.gov registry entry for NCT00651859 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bimatoprost 0.01% Ophthalmic Solution is the first listed.
NCT00651859 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00651859 about?
NCT00651859 is a clinical study titled "Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension". This study evaluates the safety and efficacy of once-daily bimatoprost 0.03% and 0.01% ophthalmic solutions compared with once-daily administered bimatoprost vehicle ophthalmic solution for 2 weeks in ethnically Japanese patients with open-angle glaucoma or ocular hypertension
What is the current status of trial NCT00651859?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2002-11. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00651859?
The interventions under investigation include: Bimatoprost 0.01% Ophthalmic Solution (DRUG), Bimatoprost 0.03% Ophthalmic Solution (DRUG), Bimatoprost Vehicle Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT00651859?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.